Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2021
August 17, 2021 at 11:57 am
Share
Getein Biotech Inc. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 600.288 million compared to CNY 379.874 million a year ago. Operating income was CNY 195.048 million compared to CNY 111.725 million a year ago. Net income was CNY 170.856 million compared to CNY 95.941 million a year ago. Basic earnings per share from continuing operations was CNY 0.47 compared to CNY 0.37 a year ago.
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
GETEIN BIOTECH, INC 
